Taiwan Liposome Company, Ltd. and Endo International plc have entered a commercialization agreement for a liposomal product. TLC will be responsible for the development and manufacturing of the product, including obtaining regulatory approval for the use, distribution, promotion and sale of the product in the United States. Upon TLC--s receipt of regulatory approval, Par Sterile Products, Endo--s sterile injectable business, will market, sell and distribute the product on an exclusive basis in the United States.

TLC is eligible to receive milestone payments as well as profits sharing from product sales in the United States.